S&P Futures
3,878.75-20.00(-0.51%)Dow Futures
31,370.00-139.00(-0.44%)Nasdaq Futures
13,213.75-66.00(-0.50%)
Cellectis S.A. (CLLS)
Chart Events
Performance Outlook
| Previous Close | 21.50 |
| Open | 21.81 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 800 |
| Day's Range | 21.81 - 23.17 |
| 52 Week Range | 7.32 - 34.71 |
| Volume | 226,340 |
| Avg. Volume | 492,818 |
| Market Cap | 977.204M |
| Beta (5Y Monthly) | 2.23 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.87 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 35.10 |
Fair Value
Related Research
- GlobeNewswire
Cellectis to Hold Fourth Quarter 2020 Earnings Call on Friday, March 5, 2021 at 8:00AM EST
NEW YORK, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced that it will report its financial results for the fourth quarter and full year ending December 31, 2020, on Thursday, March 4, 2021, after the close of the US market. The announcement will be followed by a conference call at 8:00 AM EST / 2:00 PM CET on Friday, March 5, 2021, prior to the open of the US market. The live dial-in information for the conference call is: US & Canada only: +1 (877) 407-3104International: +1 (201) 493-6792 In addition, a replay of the call will be available until March 19th, by calling +1 877-660-6853 (Toll Free US & Canada); +1 201-612-7415 (Toll Free International).Conference ID: 13716471 About Cellectis Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 21 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells. As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing lifesaving UCART product candidates to address unmet needs for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM). Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). For more information, visit www.cellectis.com. Follow Cellectis on social media: @cellectis, LinkedIn and YouTube. TALEN® is a registered trademark owned by Cellectis. For further information, please contact: Cellectis Media contacts:Margaret Gandolfo, Communications Manager, 646-628-0300, margaret.gandolfo@cellectis.com Conor McGoldrick, Zeno Group, Assistant Account Executive, 914-355-0927, Conor.Mcgoldrick@zenogroup.com IR contact:Simon Harnest, Chief Investment Officer, 646-385-9008, simon.harnest@cellectis.com Disclaimer This press release contains “forward-looking” statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “at this time,” “believe,” “expected,” forward looking”, “promising” and “will”, or the negative of these and similar expressions. These forward-looking statements, are based on our management’s current expectations and assumptions and on information currently available to management. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties, including with respect to the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to the evolving situation. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31, 2019 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. PDF available at: http://ml.globenewswire.com/Resource/Download/68a47d85-96ff-4a40-b8e9-08b4ba3eeda1
- SmarterAnalyst
Cellectis, Cytovia In $760M Partnership To Develop Natural Killer Cells; Stock Pops 9%
Cytovia Therapeutics and Cellectis, a clinical stage cell therapy company announced a $760 million research and development collaboration to develop TALEN gene edited iPSC NK and CAR NK cells. Shares of Cellectis jumped more than 9% in Tuesday’s pre-market trading session. The partnership includes development, regulatory and sales milestone payments of up to $760 million from Cytovia to Cellectis (CLLS) for the first 5 products. Cellectis is also entitled to royalty payments in single digits on net sales of all partnered products that Cytovia will commercialize. Furthermore, Cellectis will receive a $15 million stake in Cytovia stock or upfront payment of the same amount if certain conditions are not met by end of 2021 as well as an option to invest in future financing rounds. Cytovia develops allogenic gene edited Natural Killer (NK) and Chimeric Antigen Receptor (CAR) natural killer cells which are derived from induced pluripotent stem cells (iPSC). Cellectis is currently in clinical stage and focused on developing immunotherapies based on gene edited allogenic CAR T-cells. Cytovia CEO Daniel Teper said, “Cellectis has proven expertise in gene edited cell therapies and their gene editing technology, TALEN, will yield treatments with improved potency, persistence and safety for different cancers including solid tumors. We look forward to leveraging their experience to help in moving Cytovia’s CAR-NKs into clinical trials by 2022.” Notably, Cellectis has granted a worldwide license to Cytovia to its TALEN gene editing technology. This allows Cytovia to modify natural killer cells addressing multiple gene targets for therapeutic use in multiple cancer indications. (See Cellectis stock analysis on TipRanks). Cellectis shares have gained about 48% over the past year. JonesTrading analyst Soumit Roy on Dec. 6 reiterated a Buy rating on the stock with a price target of $45, implying that an additional 65.6% upside potential lies ahead. The rest of the Street is cautiously optimistic about the stock. The Moderate Buy consensus rating shows 2 Buys. Related News: Siemens Healthineers’ $16.4B Takeover Of Varian To Win EU Clearance – Report Google Clinches Content Licensing Deal With Australia’s Seven West Microsoft Showed Interest In Pinterest Takeover – Report More recent articles from Smarter Analyst: KBR Secures Five-Year $92.6M Contract With US Navy Novavax Extends SK Bioscience Partnership For Supply Of 40M COVID-19 Vaccine Doses eBay Says UK Regulator Raises Concern Over $9.2B Adevinta Deal Tuesday’s Pre-Market: Here’s What You Need To Know Before The Market Opens
- Benzinga
Cellectis, Cytovia Therapeutics Ink Gene-Edited Therapy Pact For Oncology Indications
Cytovia Therapeutics Inc and Cellectis SA (NASDAQ: CLLS) have entered into a strategic research and development collaboration to develop TALEN gene-edited induced pluripotent stem cells (iPSC) Natural Killer (NK) and Chimeric Antigen Receptor (CAR)-NK cells. Cellectis will receive up to $760 million in milestone payments from Cytovia for the first five TALEN gene-edited iPSC-derived NK products. It will also receive single-digit royalty payments on the net sales. Cellectis will receive an equity stake of $15 million in Cytovia stock or an upfront cash payment of $15 million if certain conditions are not met by December 31, 2021, as well as an option to invest in future financing rounds. The agreement utilizes Cellectis' gene-editing technology, TALEN, to yield NK and CAR-NK treatments with improved potency, persistence, and safety for various cancers, including solid tumors. Cytovia's CAR-NKs are expected to enter clinical trials by 2022. Cellectis will develop custom TALEN, Cytovia will conduct the pre-clinical evaluation, clinical development, and commercialization of the selected therapeutic candidates. Cytovia will have the worldwide license to its TALEN. Price Action: CLLS moves 9.2% higher at $29.66 in premarket trading on the last check Tuesday. See more from BenzingaClick here for options trades from BenzingaCortexyme Stops Enrollment In Mid-Stage Atuzaginstat Study In Alzheimer's DiseasePfizer's PANZYGA Wins FDA Approval For Rare Peripheral Nerves Disorder© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
